Skip to content

Released Mar 5, 2026, after the close

10-K filed Mar 5, 2026, 64 days after period end · 0001104659-26-024153

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$6.72Mderived+66.8% vs Q4 2024+32.8% vs Q3 2025
Net Income-$8.17MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$3,991,000+34.7%
Operating Incomederived-$7,369,000N/M
Operating Cash Flowderived-$6,566,000N/M
Margins · derived
Gross margin59.4%−14.2 pt vs Q4 2024
Operating margin-109.7%+97.6 pt vs Q4 2024
Net margin-121.7%+1.2 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figures
Revenue$6.72M$4.03M
Net Income-$8.17M-$4.95M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR